1-5 of 5
David John Lewis, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study

Michael Wang, MD, Nirav N. Shah, MD, Alvaro J. Alencar, MD, James N. Gerson, MD, Manish R. Patel, MD, Bita Fakhri, MDMPH, Wojciech Jurczak, MD PhD, Xuan Ni Tan, MD, Katharine L Lewis, MBBS, Timothy S. Fenske, MD, Catherine C. Coombs, MD, Ian W. Flinn, MD PhD, David John Lewis, MD, Steven Le Gouill, MD PhD, M. Lia Palomba, MD, Jennifer A. Woyach, MD, John M. Pagel, MDPhD, Nicole Lamanna, MD, Jonathon B. Cohen, MDMS, Minal Barve, MD, Paolo Ghia, MD PhD, Toby A. Eyre, Ming Yin, Binoj Nair, PhD, Donald Tsai, MD PhD, Nora C. Ku, MD, Anthony Mato, MD, Chan Yoon Cheah, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–10.
https://doi.org/10.1182/blood-2020-134314
Published: 2020
Journal Articles

Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

Martin Hutchings, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, MD PhD, Peter Johnson, MD FRCP, Kim M Linton, MBChB, PhD, Martine E.D. Chamuleau, MD PhD, David John Lewis, MD, Anna Sureda Balari, MD PhD, David Cunningham, MD FRCP, FMedSci, Roberto S Oliveri, MD PhD, Dena DeMarco, Brian Elliott, MD, Kuo-mei Chen, PhD, Pieternella J. Lugtenburg, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-133820
Published: 2020
Journal Articles

Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Andrew Davies, Josh Caddy, Katy Mercer, Geoff N Saunders, Louise Stanton, Graham P. Collins, MD DPhil, Thomas E C Cummin, MRCP MBBCh BSc, Anna Schuh, MD MRCP, PhD, Kirit M. Ardeshna, Andrew McMillan, John A. Radford, MD FMedSci, David John Lewis, MD, Adam Coleman, Gareth Griffiths, Cathy Burton, MBBChir, MA, MD FRCPath, Sharon Barrans, Peter Johnson, MD FRCP
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–39.
https://doi.org/10.1182/blood-2020-134546
Published: 2020
Journal Articles

LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study

Anthony R. Mato, MD, John M. Pagel, MDPhD, Catherine C. Coombs, MD, Nirav N. Shah, MD, Nicole Lamanna, MD, Ewa Lech-Marańda, MD PhD, Toby A. Eyre, Jennifer A. Woyach, MD, William G. Wierda, MD PhD, Chan Yoon Cheah, MBBS, Lindsey E Roeker, MD, Manish R. Patel, MD, Bita Fakhri, MDMPH, Minal Barve, MD, Constantine S. Tam, MBBS, David John Lewis, MD, James N. Gerson, MD, Alvaro J. Alencar, MD, Justin Taylor, MD, Omar Abdel-Wahab, MD, Paolo Ghia, MD PhD, Stephen J. Schuster, MD, Jessica Chen, MS, Binoj Nair, PhD, Donald Tsai, MD PhD, Nora C. Ku, MD, Matthew S. Davids, MD, Jennifer R Brown, MD PhD, Wojciech Jurczak, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–37.
https://doi.org/10.1182/blood-2020-134970
Published: 2020
Journal Articles

AVAIL-T: A Phase 2a Trial of Avelumab, and Anti-PD-L1 Antibody, in Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL)

Matthew J Ahearne, Charlotte Gaskell, BSc, MSc, Aimee E Jackson, BSc, MSc, Clare Morland, PhD, Louise Hopkins, Nadia Nawaz, Matthew A Timmins, Christopher P Fox, MD PhD, Graham P. Collins, MD DPhil, Andrew Davies, David John Lewis, MD, Kate Cwynarski, Kim Linton, MBChB, MRCP, PhD, Pam McKay, MD, Rod Johnson, Simon D. Wagner
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-136061
Published: 2020